Table 1 Patients and tumor characteristic of the selected studies
From: Oligometastasis and local ablation in the era of systemic targeted and immunotherapy
Authors (year of publication) [Reference] | Number of patients underwent SBRT | Type of Study | Primary Tumor site | Number of metastases underwent to SBRT (upper limit) | Type of oligometastases and organ involved (liver, lung, bone, nodes, brain…) | Metastases size (cm) | Median total dose/fraction | Biologically equivalent dose (Median value)a | Systemic Therapy |
|---|---|---|---|---|---|---|---|---|---|
Theelen et al. (2019) [17] | 35 | Phase II | NSCLC | 1 | Immunostimulation (Lung, Nodes, Adrenal, Bone, Skin, Liver, Pleura) | N.S. | 24/3 | 43.2 | Pembrolizumab |
Lesueur et al. (2018) [20] | 28 | Retrospective | NSCLC | 1 | Oligorecurrent (Bone, Brain, Lung) | N.S. | 25–30/1–3 | 81.6/60 | Nivolumab |
Chen et al. (2018) [15] | 37 | Retrospective | NSCLC | 2 | Olicorecurrent (Brain) | N.S. | 24–24-25/1–3-5 | 81.6/38.4/37.5 | Ipilimumab/Nivolumab/Pembrolizumab |
Schapira et al. (2017) [21] | 37 | Retrospective | NSCLC | 7 | Oligorecurrent (Brain) | 0.6 | 18–17-21/1–1-3 | 50.4/45.9/35.7 | Nivolumab/Atezolizumab/Pembrolizumab |
Bauml et al. (2019) [19] | 45 | Phase II | NSCLC | 4 | Oligoprogressive (N.S.) | N.S. | N.S. | N.S. | Pembrolizumab |
Hubbeling et al. (2018) [22] | 35 | Retrospective | NSCLC | 10 | Oligoprogressive (Brain) | N.S. | N.S. | N.S. | Nivolumab, Atezolizumab, Pembrolizumab |
Verma et al. (2018) [16] | 41 | Retrospective | NSCLC | N.S. | Oligoprogressive (Extracranial) | N.S. | 50/4 | 112,5 | Pembrolizumab |